Lidocaine solution ("A") — Competitive Intelligence Brief

Lidocaine solution ("A") (Lidocaine solution ("A")) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Anesthesia / Pain Management.

marketed Local anesthetic Voltage-gated sodium channels Anesthesia / Pain Management Small molecule

Target snapshot

Lidocaine solution ("A") (Lidocaine solution ("A")) — Hospital Universitari de Bellvitge. Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lidocaine solution ("A") TARGET	Lidocaine solution ("A")	Hospital Universitari de Bellvitge	marketed	Local anesthetic	Voltage-gated sodium channels
Mepivacaine 1%	Mepivacaine 1%	ASST Gaetano Pini-CTO	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
Ropivacaine concentration high	Ropivacaine concentration high	Oslo University Hospital	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
Prilocaine 0.5%	Prilocaine 0.5%	Bozyaka Training and Research Hospital	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
Ropivacaine + Tramadol	Ropivacaine + Tramadol	Aga Khan University	marketed	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (ropivacaine); mu-opioid receptor, norepinephrine transporter, serotonin transporter (tramadol)
MgSO4 plus Ropivacaine	MgSO4 plus Ropivacaine	Hospital Universiti Sains Malaysia	marketed	Local anesthetic adjuvant combination	Voltage-gated sodium channels (ropivacaine); NMDA receptors and calcium channels (magnesium sulfate)
dexmedetomidine-esketamine-ropivacaine combination 1	dexmedetomidine-esketamine-ropivacaine combination 1	Peking University First Hospital	marketed	Combination anesthetic/analgesic	Alpha-2 adrenergic receptor, NMDA receptor, voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

1. University of California, San Diego · 3 drugs in this class
2. Durect · 3 drugs in this class
3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
4. Wake Forest University Health Sciences · 3 drugs in this class
5. Medical University of Vienna · 3 drugs in this class
6. Imperial College London · 2 drugs in this class
7. Hvidovre University Hospital · 2 drugs in this class
8. Innocoll · 2 drugs in this class
9. George Washington University · 2 drugs in this class
10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class